Although advertisements promote the drug as safe and effective, with few long-term side effects, Latham and other former users are now pursuing Ozempic lawsuits and Wegovy lawsuits against Novo Nordisk, each raising similar allegations that the widespread use of the drugs has made it clear that the drug label fails to adequately warn about the risk of severe and long-lasting gastroparesis side effects
#AntibodyDrugDiscovery #GPCR #BiopharmaInnovation #AIDrugDiscovery #LifeScienceInvestment To view or add a comment, sign in NBHL and FRONTEO Enter PoC Research Agreement to Accelerate Antibody Drug Discovery Leveraging AI and GPCR Antibody Platforms NBHL announced that it has entered into a Proof-of-Concept (PoC) research agreement with FRONTEO, Inc
Similarly, Semaglutide , the active ingredient in Ozempic and Wegovy , has also demonstrated impressive outcomes in multiple clinical studies
GIP receptors are found throughout the body, and their activation improves how cells respond to insulin (insulin sensitivity) and appears to promote more favorable fat distribution (less visceral fat around organs, more subcutaneous fat under the skin)
